U.S. Markets closed
  • S&P Futures

    4,281.50
    -5.00 (-0.12%)
     
  • Dow Futures

    33,956.00
    -25.00 (-0.07%)
     
  • Nasdaq Futures

    13,507.50
    -15.75 (-0.12%)
     
  • Russell 2000 Futures

    1,997.20
    -4.50 (-0.22%)
     
  • Crude Oil

    90.64
    +0.14 (+0.15%)
     
  • Gold

    1,771.00
    -0.20 (-0.01%)
     
  • Silver

    19.41
    -0.06 (-0.30%)
     
  • EUR/USD

    1.0084
    -0.0008 (-0.0807%)
     
  • 10-Yr Bond

    2.8800
    -0.0130 (-0.45%)
     
  • Vix

    19.56
    -0.34 (-1.71%)
     
  • GBP/USD

    1.1917
    -0.0016 (-0.1347%)
     
  • USD/JPY

    136.1280
    +0.2660 (+0.1958%)
     
  • BTC-USD

    23,091.34
    -302.34 (-1.29%)
     
  • CMC Crypto 200

    548.56
    -9.17 (-1.64%)
     
  • FTSE 100

    7,541.85
    +26.10 (+0.35%)
     
  • Nikkei 225

    28,942.14
    -280.63 (-0.96%)
     

Reneo Pharmaceuticals to Participate in SVB Leerink Virtual Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

IRVINE, Calif., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that it will be hosting a fireside chat and participating in one-on-one investor meetings at SVB Leerink’s Virtual Global Healthcare Conference taking place February 14-18, 2022.

Presentation details are as follows:

Date: Friday, February 18, 2022
Time: 1:00 PM ET
Format: Fireside chat

About Reneo Pharmaceuticals

Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Reneo is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria.

Contacts:

Joyce Allaire
Managing Director
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

Vinny Jindal
Chief Financial Officer
Reneo Pharmaceuticals, Inc.
investors@reneopharma.com